2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in

Aisling Capital

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
  • United States
Investment stages
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Therapeutics
  • Biopharmaceuticals
  • Medical Technology
  • Healthcare Products
  • Healthcare Services
  • Life Sciences
About
Aisling Capital is a New York-based investment firm focused on backing companies in therapeutics and healthcare products. Their focus spans biopharma, medical technology, and healthcare services across the United States. The firm supports life science companies from Series A through growth stage.
Min check size
$1M
Max check size
$10M
Fund size
NPS

Investment Thesis

Aisling Capital is a Series A to growth stage investment firm deploying capital across therapeutics, biopharmaceuticals, medical technology, and healthcare products and services. They invest in companies developing and commercializing differentiated therapeutic assets, with a focus on clinically de-risked programs and platforms addressing significant unmet medical need. The firm differentiates itself through multi-decade, multi-fund continuity in life sciences and deep scientific and transactional expertise across drug development cycles.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Founded in 2000 by Steve Elms, Andrew Schiff, and Dennis Purcell. Team includes Managing Partners Andrew Schiff, Steve Elms, and Dennis Purcell. Manages $1.9B+ across five funds since inception. Focused on life sciences and healthcare investments across biopharmaceuticals, medical devices, diagnostics, and healthcare services. Portfolio includes companies advancing therapeutics and life science technologies.

Aisling Capital Contacts Information

Primary contact

Secondary contact

Team

Steven Elms-Managing Partner

Andrew Schiff-Managing Partner

Eric Aguiar-Partner

Aftab Kherani-Partner

Wonpyo Yun-Principal

Sunny Reddy-Principal

Katie Tansey-VP Investor Relations & Marketing

Robert Wenzel-title unconfirmed

Portfolio

Aclaris Therapeutics

Adams Respiratory Therapeutics

ADMA Biologics

Advion

Aeglea BioTherapeutics

Agile Therapeutics

Aimmune Therapeutics

Ajax Health

Allos Therapeutics

Ambit Biosciences

Antios Therapeutics

Aragon Pharmaceuticals

Archimica

Arcus Biosciences

ARMGO Pharma

ARMO BioSciences

Ascendis Pharma

Aton Pharma

Atreca

Audentes Therapeutics

Auxilium Pharmaceuticals

AVANZA Laboratories

AVROBIO

Axcan Pharma

Barrier Therapeutics

Bicara Therapeutics

Bioenvision

Biohaven Pharmaceuticals

Biomea Fusion

BridgeBio Pharma

BridgeBio Oncology Therapeutics

CalciMedica

Cardiokine

Catalent

Cempra

Chimerix

Cidara Therapeutics

Clovis Oncology

CollaGenex Pharmaceuticals

Colorescience

COMPASS Pathways

Cynapsus Therapeutics

Cytos Biotechnology

Dermira

Dren Bio

Durata Therapeutics

EarLens

Eidos Therapeutics

Elevation Oncology

Esperion Therapeutics

F2G

Forge Biologics

Garuda Therapeutics

Global Blood Therapeutics

GondolaBio

GTx

Harmony Biosciences

Infinity Pharmaceuticals

Intercept Pharmaceuticals

Intersect ENT

LENSAR

Lombard Medical

Loxo Oncology

MAP Pharmaceuticals

Marker Therapeutics

Medical Knowledge Group

MEI Pharma

Menlo Therapeutics

Mindful Health Solutions

Miramar Labs

Monte Rosa Therapeutics

Myogen

Nabriva

NextWave Pharmaceuticals

Novazyme Pharmaceuticals

Nuvation Bio

ObsEva

Oculex Pharmaceuticals

OnKure Therapeutics

Paratek Pharmaceuticals

PellePharm

Pernix Therapeutics

Pharmaron

Planet Biopharmaceuticals

Poseida Therapeutics

PowerVision

PreCision Dermatology

Prolacta Bioscience

Promentis Pharmaceuticals

Protagonist Therapeutics

Quintiles Transnational

Roka Bioscience

Scholar Rock

Seragon Pharmaceuticals

Sirion Therapeutics

SkinMedica

Sorrento Therapeutics

Spirox

Spruce Biosciences

Spyre Therapeutics

Syndax Pharmaceuticals

Synergy Pharmaceuticals

Syros Pharmaceuticals

T2 Biosystems

Talaris Therapeutics

Topaz Pharmaceuticals

TransEnterix

Treeline Biosciences

TRIA Beauty

UroGen Pharma

Verona Pharma

Versartis

ViewRay

Viracta Pharmaceuticals

VIVUS

Wugen

Zavante Therapeutics

ZELTIQ Aesthetics

Zosano Pharma

Allotera Therapeutics

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp